title: PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
abstract: OBJECTIVE
  Peptide YY(3-36) (PYY(3-36)), a Y2 receptor agonist, and oxyntomodulin, a glucagon-like peptide 1 (GLP-1) receptor agonist, are cosecreted by intestinal L-cells after each meal. Separately each hormone acts as an endogenous satiety signal and reduces appetite in humans when infused intravenously. The aim of the current study was to investigate whether the anorectic effects of PYY(3-36) and oxyntomodulin can be additive.
  
  
  METHODS
  Twelve overweight or obese human volunteers underwent a randomized, double-blinded, placebo-controlled study. An ad libitum test meal was used to measure energy intake during intravenous infusions of either PYY(3-36) or oxyntomodulin or combined PYY(3-36)/oxyntomodulin.
  
  
  RESULTS
  Energy intake during coadministration of PYY(3-36) and oxyntomodulin was reduced by 42.7% in comparison with the saline control and was significantly lower than that during infusions of either hormone alone.
  
  
  CONCLUSIONS
  The anorectic effects of PYY(3-36) and oxyntomodulin can be additive in overweight and obese humans. Coadministration of Y2 receptor agonists and GLP-1 receptor agonists may be a useful treatment strategy for obesity.
authors.affiliation: Department of Investigative Medicine, Imperial College London, UK
authors.forename: Benjamin C T
authors.initials: BC
authors.lastname: Field
authors.forename: Alison M
authors.initials: AM
authors.lastname: Wren
authors.forename: Veronique
authors.initials: V
authors.lastname: Peters
authors.forename: Kevin C R
authors.initials: KC
authors.lastname: Baynes
authors.forename: Niamh M
authors.initials: NM
authors.lastname: Martin
authors.forename: Michael
authors.initials: M
authors.lastname: Patterson
authors.forename: Sara
authors.initials: S
authors.lastname: Alsaraf
authors.forename: Vian
authors.initials: V
authors.lastname: Amber
authors.forename: Katie
authors.initials: K
authors.lastname: Wynne
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Ghatei
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Bloom
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D004435:Eating / Q000187:drug effects*; D002149:Energy Intake / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D050177:Overweight / Q000188:drug therapy* / Q000378:metabolism; D053772:Oxyntomodulin / Q000008:administration & dosage* / Q000378:metabolism; D018579:Patient Selection; D010446:Peptide Fragments; D019894:Peptide YY / Q000008:administration & dosage* / Q000378:metabolism; D011795:Surveys and Questionnaires
chemical_list: D053772:Oxyntomodulin; D010446:Peptide Fragments; D019894:Peptide YY; C061785:peptide YY (3-36)